JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

RUNX1 Is an Independent Prognostic Marker Involved in Immune Infiltration and Therapeutic Responses in Clear Cell Renal Cell Carcinoma Patients Through Cluster Regulation With RUNX2

  • 0Department of Urology, The Fourth Affiliated Hospital of Soochow University, Suzhou, China.
Immunity, Inflammation and Disease +

|

August 14, 2025

|

August 14, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

RUNX1 and RUNX2 are upregulated in clear cell renal cell carcinoma (ccRCC), promoting an immunosuppressive tumor microenvironment. RUNX1 shows potential as a prognostic biomarker and predictor of immunotherapy response in ccRCC patients.

Area Of Science

  • Oncology
  • Immunology
  • Genetics

Background

  • Immunomodulation plays a critical role in clear cell renal cell carcinoma (ccRCC) development and patient outcomes.
  • The specific roles and regulatory mechanisms of the Runt-related transcription factor (RUNX) gene family in ccRCC immunity are not fully understood.

Purpose Of The Study

  • To investigate the expression patterns of RUNX family genes in ccRCC.
  • To elucidate the association between RUNX gene expression, the tumor immune microenvironment, and patient prognosis.
  • To evaluate the potential of RUNX genes as biomarkers for immunotherapy response and clinical prediction in ccRCC.

Main Methods

  • Differential gene expression analysis using TCGA and GEO datasets.
  • Gene Ontology (GO) and KEGG pathway enrichment analyses.
  • Immune cell infiltration analysis using MCPCounter and CIBERSORT algorithms.
  • Prognostic model construction using multi-Cox regression analysis.

Main Results

  • RUNX1, RUNX2, and RUNX3 showed elevated expression in ccRCC.
  • High RUNX1/2 expression correlated with advanced clinicopathological features and poor prognosis.
  • RUNX1/2 are implicated in creating an immunosuppressive tumor microenvironment and RUNX1 may impede immunotherapy efficacy.
  • RUNX1 was identified as an independent prognostic indicator, and a RUNX1-based model achieved an AUC of 0.872 for prediction.

Conclusions

  • RUNX1/2 genes are significantly involved in ccRCC progression, prognosis, and immune microenvironment modulation.
  • RUNX1 serves as a promising biomarker for predicting ccRCC immunotherapy response.
  • A RUNX1-based prognostic model offers potential for improved clinical prediction in ccRCC.

Keywords: